{
  "prompt": {
    "prompt": "Original Transcript:\n**Professional Medical Clerking – SBAR Format**  \n\n---  \n\n### **SITUATION:**  \n**Patient Demographics:**  \n- **Name:** Ms. X (DOB: 15/05/1985, 39yo)  \n- **Gestation:** N/A (G4P2, previous SVD x2, LSCS x1)  \n- **Presenting Complaint:** Abnormal uterine bleeding (AUB) – heavy menstrual bleeding (HMB) with intermenstrual bleeding (IMB) for 3/12, worsening over last 2/52.  \n- **Key Clinical Issue:** Persistent AUB with associated fatigue (likely secondary to iron deficiency anemia). No hemodynamic instability at present.  \n\n### **BACKGROUND:**  \n**Relevant PMHx:**  \n- **OBGYN Hx:**  \n  - G4P2 (2x SVD, 1x LSCS for FTP, 1x TOP)  \n  - Previous IUD (Mirena®) removed 6/12 ago due to expulsion  \n  - No known fibroids or endometriosis  \n- **Medical Hx:**  \n  - Hypothyroidism (on levothyroxine 75mcg OD)  \n  - Obesity (BMI 32)  \n  - No known coagulopathy  \n- **Surgical Hx:**  \n  - LSCS (2018)  \n  - Appendicectomy (2005)  \n- **Medications:**  \n  - Levothyroxine 75mcg OD  \n  - NSAIDs PRN for dysmenorrhea (no recent use)  \n- **Allergies:** NKDA  \n- **Social Hx:**  \n  - Non-smoker, occasional ETOH  \n  - Works as a teacher, moderately active  \n\n**Risk Factors for AUB:**  \n- Obesity (↑ endometrial hyperplasia risk)  \n- Hypothyroidism (may exacerbate HMB)  \n- Previous IUD expulsion (possible structural cause)  \n\n### **ASSESSMENT:**  \n**Clinical Findings (0800 hours):**  \n- **Vitals:**  \n  - BP: 128/78 mmHg  \n  - HR: 88 bpm (regular)  \n  - Temp: 36.7°C  \n  - SpO₂: 98% RA  \n  - RR: 14/min  \n- **General Exam:**  \n  - Pale conjunctivae (clinical anemia)  \n  - No signs of hemodynamic compromise  \n- **Abdo Exam:**  \n  - Soft, non-tender, no palpable masses  \n- **PV Exam (consented & chaperoned):**  \n  - No active bleeding at time of exam  \n  - Cervix appears normal, no cervical excitation  \n  - Uterus anteverted, non-tender, normal size  \n  - No adnexal masses  \n\n**Investigations:**  \n- **Bloods (FBC, LFTs, U&Es, CRP, TFTs, coagulation screen):**  \n  - Hb: 98 g/L (↓ from 112 g/L 6/12 ago)  \n  - MCV: 78 fL (microcytic)  \n  - Ferritin: 12 μg/L (↓)  \n  - TSH: 2.1 mIU/L (well-controlled)  \n  - Platelets: 220 x10⁹/L  \n  - INR/APTT: Normal  \n- **Imaging:**  \n  - **TV USS:**  \n    - Endometrial thickness: 12mm (heterogeneous)  \n    - No fibroids/polyps seen  \n    - Normal adnexa  \n  - **Pipelle biopsy (awaiting histology)**  \n\n**Differential Diagnosis (PALM-COEIN):**  \n1. **Polyp/Adenomyosis** (USS inconclusive, biopsy pending)  \n2. **Endometrial hyperplasia** (↑ risk due to obesity)  \n3. **Coagulopathy** (unlikely given normal coagulation)  \n4. **Ovulatory dysfunction** (secondary to hypothyroidism?)  \n5. **Iatrogenic** (none identified)  \n\n### **RECOMMENDATION:**  \n**Immediate Management:**  \n- **Iron supplementation:** Ferrous sulfate 200mg BD + vitamin C (monitor Hb in 4/52)  \n- **Hormonal therapy:**  \n  - Start norethisterone 5mg TDS for 21/7 (to regulate bleeding)  \n  - Consider Mirena® IUD reinsertion if biopsy normal  \n- **Analgesia:** Mefenamic acid 500mg TDS PRN (if dysmenorrhea)  \n\n**Monitoring & Follow-Up:**  \n- **Repeat Hb in 4/52** (target >110 g/L)  \n- **Await endometrial biopsy results** (exclude hyperplasia/malignancy)  \n- **GYN OPD follow-up in 6/52** (consider hysteroscopy if bleeding persists)  \n\n**Further Investigations if Needed:**  \n- **Hysteroscopy + biopsy** if USS/biopsy inconclusive  \n- **Thyroid antibody testing** if TFTs fluctuate  \n\n**Contingencies:**  \n- If hemodynamically unstable → admit for IV iron/transfusion  \n- If biopsy shows hyperplasia → consider progestogens/hysterectomy (if completed family)  \n\n---  \n**Documented by:** [Your Name] (FY2)  \n**Reviewed by:** [Consultant Name] (Obstetrics & Gynaecology)  \n**Time/Date:** 0800 hours, 05/06/2024  \n\n*(This is a fictional case for educational purposes only.)*\n\nGuideline Analysis:\nClinical transcript analysis for guideline compliance check against: Management of Endometrial Hyperplasia. This analysis focuses on identifying areas where the clinical documentation can be improved according to the specific guideline requirements.\n\nGuideline: Management of Endometrial Hyperplasia\n\n\nFull Guideline Content:\nManagement of Endometrial Hyperplasia\nRisk factors for endometrial hyperplasia should be identified and monitored. The WHO classification should be used for classification. Diagnosis and surveillance methods include endometrial sampling and hysteroscopy. Progestogens are effective in managing hyperplasia without atypia, with LNG-IUS being the first-line treatment. Treatment should last at least 6 months with follow-up biopsies. Surgical management may be considered in certain cases. Atypical hyperplasia should be managed with total hysterectomy. Women wishing to preserve fertility should be counseled about risks. HRT should be used cautiously. Women on adjuvant treatment for breast cancer should be monitored for hyperplasia. Endometrial hyperplasia confined to a polyp should be managed with complete removal. Regular surveillance is recommended. Management in women wishing to conceive should focus on achieving disease regression before attempting conception.\n\nThe 2014 WHO classification separates endometrial hyperplasia into two groups based on cytological atypia. Diagnosis requires histological examination. Surveillance methods include endometrial sampling and transvaginal ultrasound. Hysteroscopy may be necessary for further assessment. CT or MRI are not routinely recommended. Biomarkers have not been found to be clinically useful. Management of hyperplasia without atypia includes addressing reversible risk factors and considering progestogen treatment if regression does not occur. Weight loss and hormone therapy should be reviewed. Anovulatory cycles may regress with ovulation. Progestogen treatment may reduce the risk of progression to cancer. More evidence is needed to determine the appropriate management approach.\n\nMany women with endometrial hyperplasia may require treatment due to the risk of progression to cancer. The first-line medical treatment for hyperplasia without atypia is the levonorgestrel-releasing intrauterine system (LNG-IUS) due to its higher regression rate and fewer adverse effects compared to oral progestogens. Treatment should last for a minimum of 6 months to induce regression. Endometrial surveillance should be done every 6 months, with at least two consecutive negative biopsies before discharge. Surgical management, such as hysterectomy, should be considered if there is no regression after 12 months of treatment or if there is relapse. A laparoscopic approach to hysterectomy is preferred. Endometrial ablation is not recommended. Annual endometrial biopsies can be considered for high-risk women. Ultimately, treatment decisions should be based on individual factors and patient preferences.\n\nEndometrial ablation is not recommended for atypical hyperplasia, as complete endometrial destruction cannot be guaranteed, and there is a risk of tissue regeneration. Total hysterectomy is advised for women with atypical hyperplasia to reduce the risk of underlying malignancy or cancer progression. In cases where fertility preservation is desired or surgery is not suitable, first-line treatment with LNG-IUS is recommended, with oral progestogens as an alternative. Women should be counselled about the risks of fertility-sparing therapy, including the potential for cancer progression. Follow-up for women not undergoing hysterectomy should include routine endometrial surveillance with biopsies every 3 months until negative results are obtained. Women with atypical hyperplasia who wish to conceive should achieve disease regression before attempting to conceive and may consider assisted reproduction for higher live birth rates and to prevent relapse. It is important to monitor disease regression and consider referral to a fertility specialist for further assessment and treatment options.\n\n- A small trial showed that LNG-IUS treatment was more effective than observation alone in regressing simple hyperplasia and improving pregnancy rates in women with PCOS.\n- Hysterectomy is recommended for women with atypical endometrial hyperplasia once fertility is no longer required.\n- Systemic estrogen-only HRT should not be used in women with a uterus.\n- Women with endometrial hyperplasia on HRT should consider switching to continuous progestogen intake using LNG-IUS or continuous combined HRT.\n- Tamoxifen users should be aware of the increased risk of endometrial hyperplasia and cancer.\n- Aromatase inhibitors do not increase the risk of endometrial pathology or vaginal bleeding.\n- LNG-IUS may reduce the incidence of endometrial polyps and hyperplasia in women on tamoxifen.\n- Women with endometrial hyperplasia while on tamoxifen should reassess the need for tamoxifen with their oncologist.\n- Complete removal of endometrial polyps is recommended for management.\n- Recommendations for future research include evaluating the role of biomarkers in diagnosing endometrial hyperplasia and studying the effect of weight loss on regression of the condition.\n- Auditable topics include advising weight loss for obese women with endometrial hyperplasia and ensuring appropriate follow-up biopsies.\n- Useful links and support groups for endometrial hyperplasia.\n\nAccuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia. Investigation of post-menopausal bleeding. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. Asymptomatic endometrial thickening. Endometrial thickness screening in premenopausal women with abnormal uterine bleeding. Long-term Consequences of Polycystic Ovary Syndrome. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Diagnostic dilation and curettage: a reappraisal. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20–74 years. Hysteroscopy with directed biopsy versus dilatation and curettage for the diagnosis of endometrial hyperplasia and cancer in perimenopausal women. A randomised trial comparing the H Pipelle with the standard Pipelle for endometrial sampling at ‘no-touch’ hysteroscopy. Ambulatory hysteroscopy. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia. The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women. Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. The behavior of endometrial hyperplasia: a prospective study. Bariatric surgery and endometrial pathology in asymptomatic morbidly obese women. Women at extreme risk for obesity-related carcinogenesis: Baseline endometrial pathology and impact of bariatric surgery on weight, metabolic profiles and quality of life. Endometrial histology in severely obese bariatric surgery candidates: an exploratory analysis. Referring survivors of endometrial cancer and complex atypical hyperplasia to bariatric specialists. Phytoestrogen consumption and endometrial cancer risk: a population-based case–control study. Histopathological findings of the endometrium in patients with dysfunctional uterine bleeding. Ovarian cysts in postmenopausal women. Management of suspected ovarian masses in premenopausal women. Inhibin as a marker for granulosa cell tumor. Granulosa cell tumor of the ovary. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia. Safer prescribing of therapeutic norethisterone for women at risk of venous thromboembolism. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in the treatment of simple endometrial hyperplasia without atypia. LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia. Levonorgestrel-releasing intrauterine system is an efficient therapeutic modality for simple endometrial hyperplasia. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Levonorgestrel-releasing intrauterine system as an effective treatment option for endometrial hyperplasia. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. The distal fallopian tube as the origin of non-uterine pelvic high-grade serous carcinomas. Supracervical hyster\n\nLong-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 2013;121:709–16. Intrauterine surgery using a new coaxial bipolar electrode in normal saline solution (Versapoint): a pilot study. Fertil Steril 1999;72:740–3. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol 2012; 207:266.e1–12. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet Gynecol 2010;116:365–73. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol 2012;124:542–8. American College of Obstetricians and Gynecologists, Society of Gynecologic Oncology. Practice Bulletin No. 149: Endometrial cancer. Obstet Gynecol 2015;125:1006–26. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol 2013;129:7–11. Fertility problems: assessment and treatment. NICE clinical guideline 156. Manchester: NICE; 2013. Efficacy of the levonorgestrel-releasing intrauterine system on IVF-ET outcomes in PCOS with simple endometrial hyperplasia. Reprod Sci 2015;22:758–66. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA1996;275:370–5.\n\nCommittee members from various locations contributed to the development of the guideline. The final version is the responsibility of the Guidelines Committee of the RCOG.\n\nPlease extract actionable suggestions from this analysis and format them as specified. For each suggestion, include detailed context with relevant quoted text from the guideline to help the user understand the reasoning behind the recommendation.",
    "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nCRITICAL CLINICAL REASONING REQUIREMENTS:\n- You must first understand the specific clinical scenario and current diagnosis from the transcript\n- Carefully assess whether each potential recommendation is APPROPRIATE and INDICATED for this specific case\n- Apply the fundamental principle: \"Will this investigation or intervention change management or improve patient care in this specific scenario?\"\n- Consider the clinical context: is this an acute emergency, established diagnosis, or uncertain diagnostic situation?\n- Distinguish between situations where additional testing is needed vs. where diagnosis is already established\n- Only recommend interventions that would genuinely improve patient care in THIS specific scenario\n\nGENERAL CLINICAL APPROPRIATENESS PRINCIPLES:\n- Do NOT suggest diagnostic investigations when the diagnosis is already established through adequate clinical and/or imaging findings\n- Do NOT recommend interventions that conflict with the current evidence-based management plan\n- Do NOT suggest serial monitoring of biomarkers when the clinical picture and imaging provide sufficient diagnostic certainty\n- Consider whether additional investigations would actually change the management approach\n- Evaluate the timing: is this the appropriate point in the clinical course for this intervention?\n- Apply cost-benefit analysis: does the potential benefit justify the intervention in this specific case?\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing OR description of missing element\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"detailed explanation of why this change is suggested, including relevant quoted text from the guideline in quotation marks, and confirmation that this recommendation is appropriate for the specific clinical scenario\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines for originalText field:\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\n- For ADDITIONS (missing elements): Use descriptive text like \"Missing: cervical length screening documentation\" or \"Gap: no discussion of antenatal corticosteroids\"\n- DO NOT use phrases like \"no additional cervical length screening ordered\" unless those exact words appear in the transcript\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\n\nImportant guidelines for context field:\n- Provide detailed explanations including WHY the change is needed AND why it's appropriate for this specific case\n- Include specific quoted text from the guideline using quotation marks (e.g., \"According to the guideline: 'All women should receive screening for...'\")\n- Reference specific guideline recommendations or requirements\n- Explain the clinical rationale behind the suggestion\n- EXPLICITLY state why this recommendation is indicated in this particular clinical scenario\n- Make the context informative and educational\n\nOther important guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis AND clinically appropriate for the specific scenario\n- Make suggestions specific and actionable\n- For modifications, ensure original text selections are precise and findable in the transcript\n- Prioritize suggestions based on clinical importance and appropriateness\n- If no clinically appropriate suggestions can be made, return {\"suggestions\": []}\n- When in doubt about appropriateness, err on the side of NOT making the suggestion",
    "transcript_length": 3778,
    "analysis_length": 249,
    "guideline_id": "gtg-2014-endometrial-hyperplasia-pdf",
    "guideline_title": "Management of Endometrial Hyperplasia"
  },
  "response": "{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Consider Mirena® IUD reinsertion if biopsy normal\",\n      \"suggestedText\": \"Recommend LNG-IUS (Mirena®) as first-line treatment if biopsy shows hyperplasia without atypia\",\n      \"context\": \"According to the guideline: 'The first-line medical treatment for hyperplasia without atypia is the levonorgestrel-releasing intrauterine system (LNG-IUS) due to its higher regression rate and fewer adverse effects compared to oral progestogens.' This patient has risk factors for endometrial hyperplasia (obesity, persistent AUB) and the current management plan should be updated to reflect guideline recommendations for first-line therapy if hyperplasia is confirmed.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"First-line treatment for hyperplasia without atypia\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"GYN OPD follow-up in 6/52 (consider hysteroscopy if bleeding persists)\",\n      \"suggestedText\": \"Schedule follow-up with endometrial surveillance every 6 months if hyperplasia confirmed, with at least two consecutive negative biopsies before discharge\",\n      \"context\": \"The guideline states: 'Endometrial surveillance should be done every 6 months, with at least two consecutive negative biopsies before discharge.' Given this patient's risk factors and current presentation, this more structured follow-up plan is indicated if hyperplasia is confirmed to monitor for regression and prevent progression.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Endometrial surveillance recommendations\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Missing: explicit documentation of WHO classification system application for any biopsy results\",\n      \"suggestedText\": \"Document biopsy results using WHO classification system (hyperplasia with/without atypia) when available\",\n      \"context\": \"The guideline specifies: 'The 2014 WHO classification separates endometrial hyperplasia into two groups based on cytological atypia.' This classification is critical for determining appropriate management and should be explicitly documented in the patient record when biopsy results are available.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"WHO classification system\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Start norethisterone 5mg TDS for 21/7 (to regulate bleeding)\",\n      \"suggestedText\": \"If biopsy shows hyperplasia without atypia, consider switching from oral norethisterone to LNG-IUS as primary treatment\",\n      \"context\": \"The guideline recommends: 'The first-line medical treatment for hyperplasia without atypia is the levonorgestrel-releasing intrauterine system (LNG-IUS) due to its higher regression rate and fewer adverse effects compared to oral progestogens.' While norethisterone is appropriate for acute bleeding control, long-term management should follow guideline recommendations if hyperplasia is confirmed.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Comparison of treatment efficacy\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Gap: no documented discussion of weight loss as management strategy\",\n      \"suggestedText\": \"Add recommendation for weight loss counseling given obesity as a risk factor for endometrial hyperplasia\",\n      \"context\": \"The guideline emphasizes: 'Weight loss and hormone therapy should be reviewed' for managing endometrial hyperplasia. This patient's BMI of 32 significantly increases her risk and weight loss should be incorporated as part of the management plan to address this modifiable risk factor.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Reversible risk factors\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"If biopsy shows hyperplasia → consider progestogens/hysterectomy (if completed family)\",\n      \"suggestedText\": \"If biopsy shows atypical hyperplasia → recommend total hysterectomy (given patient has completed family)\",\n      \"context\": \"The guideline states: 'Total hysterectomy is advised for women with atypical hyperplasia to reduce the risk of underlying malignancy or cancer progression.' As this patient is G4P2 and has completed her family, this would be the recommended management for atypical hyperplasia per guidelines.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Management of atypical hyperplasia\"\n    }\n  ]\n}",
  "endpoint": "dynamicAdvice",
  "timestamp": "2025-07-17T13-52-22",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\n**Professional Medical Clerking – SBAR Format**  \\n\\n---  \\n\\n### **SITUATION:**  \\n**Patient Demographics:**  \\n- **Name:** Ms. X (DOB: 15/05/1985, 39yo)  \\n- **Gestation:** N/A (G4P2, previous SVD x2, LSCS x1)  \\n- **Presenting Complaint:** Abnormal uterine bleeding (AUB) – heavy menstrual bleeding (HMB) with intermenstrual bleeding (IMB) for 3/12, worsening over last 2/52.  \\n- **Key Clinical Issue:** Persistent AUB with associated fatigue (likely secondary to iron deficiency anemia). No hemodynamic instability at present.  \\n\\n### **BACKGROUND:**  \\n**Relevant PMHx:**  \\n- **OBGYN Hx:**  \\n  - G4P2 (2x SVD, 1x LSCS for FTP, 1x TOP)  \\n  - Previous IUD (Mirena®) removed 6/12 ago due to expulsion  \\n  - No known fibroids or endometriosis  \\n- **Medical Hx:**  \\n  - Hypothyroidism (on levothyroxine 75mcg OD)  \\n  - Obesity (BMI 32)  \\n  - No known coagulopathy  \\n- **Surgical Hx:**  \\n  - LSCS (2018)  \\n  - Appendicectomy (2005)  \\n- **Medications:**  \\n  - Levothyroxine 75mcg OD  \\n  - NSAIDs PRN for dysmenorrhea (no recent use)  \\n- **Allergies:** NKDA  \\n- **Social Hx:**  \\n  - Non-smoker, occasional ETOH  \\n  - Works as a teacher, moderately active  \\n\\n**Risk Factors for AUB:**  \\n- Obesity (↑ endometrial hyperplasia risk)  \\n- Hypothyroidism (may exacerbate HMB)  \\n- Previous IUD expulsion (possible structural cause)  \\n\\n### **ASSESSMENT:**  \\n**Clinical Findings (0800 hours):**  \\n- **Vitals:**  \\n  - BP: 128/78 mmHg  \\n  - HR: 88 bpm (regular)  \\n  - Temp: 36.7°C  \\n  - SpO₂: 98% RA  \\n  - RR: 14/min  \\n- **General Exam:**  \\n  - Pale conjunctivae (clinical anemia)  \\n  - No signs of hemodynamic compromise  \\n- **Abdo Exam:**  \\n  - Soft, non-tender, no palpable masses  \\n- **PV Exam (consented & chaperoned):**  \\n  - No active bleeding at time of exam  \\n  - Cervix appears normal, no cervical excitation  \\n  - Uterus anteverted, non-tender, normal size  \\n  - No adnexal masses  \\n\\n**Investigations:**  \\n- **Bloods (FBC, LFTs, U&Es, CRP, TFTs, coagulation screen):**  \\n  - Hb: 98 g/L (↓ from 112 g/L 6/12 ago)  \\n  - MCV: 78 fL (microcytic)  \\n  - Ferritin: 12 μg/L (↓)  \\n  - TSH: 2.1 mIU/L (well-controlled)  \\n  - Platelets: 220 x10⁹/L  \\n  - INR/APTT: Normal  \\n- **Imaging:**  \\n  - **TV USS:**  \\n    - Endometrial thickness: 12mm (heterogeneous)  \\n    - No fibroids/polyps seen  \\n    - Normal adnexa  \\n  - **Pipelle biopsy (awaiting histology)**  \\n\\n**Differential Diagnosis (PALM-COEIN):**  \\n1. **Polyp/Adenomyosis** (USS inconclusive, biopsy pending)  \\n2. **Endometrial hyperplasia** (↑ risk due to obesity)  \\n3. **Coagulopathy** (unlikely given normal coagulation)  \\n4. **Ovulatory dysfunction** (secondary to hypothyroidism?)  \\n5. **Iatrogenic** (none identified)  \\n\\n### **RECOMMENDATION:**  \\n**Immediate Management:**  \\n- **Iron supplementation:** Ferrous sulfate 200mg BD + vitamin C (monitor Hb in 4/52)  \\n- **Hormonal therapy:**  \\n  - Start norethisterone 5mg TDS for 21/7 (to regulate bleeding)  \\n  - Consider Mirena® IUD reinsertion if biopsy normal  \\n- **Analgesia:** Mefenamic acid 500mg TDS PRN (if dysmenorrhea)  \\n\\n**Monitoring & Follow-Up:**  \\n- **Repeat Hb in 4/52** (target >110 g/L)  \\n- **Await endometrial biopsy results** (exclude hyperplasia/malignancy)  \\n- **GYN OPD follow-up in 6/52** (consider hysteroscopy if bleeding persists)  \\n\\n**Further Investigations if Needed:**  \\n- **Hysteroscopy + biopsy** if USS/biopsy inconclusive  \\n- **Thyroid antibody testing** if TFTs fluctuate  \\n\\n**Contingencies:**  \\n- If hemodynamically unstable → admit for IV iron/transfusion  \\n- If biopsy shows hyperplasia → consider progestogens/hysterectomy (if completed family)  \\n\\n---  \\n**Documented by:** [Your Name] (FY2)  \\n**Reviewed by:** [Consultant Name] (Obstetrics & Gynaecology)  \\n**Time/Date:** 0800 hours, 05/06/2024  \\n\\n*(This is a fictional case for educational purposes only.)*\\n\\nGuideline Analysis:\\nClinical transcript analysis for guideline compliance check against: Management of Endometrial Hyperplasia. This analysis focuses on identifying areas where the clinical documentation can be improved according to the specific guideline requirements.\\n\\nGuideline: Management of Endometrial Hyperplasia\\n\\n\\nFull Guideline Content:\\nManagement of Endometrial Hyperplasia\\nRisk factors for endometrial hyperplasia should be identified and monitored. The WHO classification should be used for classification. Diagnosis and surveillance methods include endometrial sampling and hysteroscopy. Progestogens are effective in managing hyperplasia without atypia, with LNG-IUS being the first-line treatment. Treatment should last at least 6 months with follow-up biopsies. Surgical management may be considered in certain cases. Atypical hyperplasia should be managed with total hysterectomy. Women wishing to preserve fertility should be counseled about risks. HRT should be used cautiously. Women on adjuvant treatment for breast cancer should be monitored for hyperplasia. Endometrial hyperplasia confined to a polyp should be managed with complete removal. Regular surveillance is recommended. Management in women wishing to conceive should focus on achieving disease regression before attempting conception.\\n\\nThe 2014 WHO classification separates endometrial hyperplasia into two groups based on cytological atypia. Diagnosis requires histological examination. Surveillance methods include endometrial sampling and transvaginal ultrasound. Hysteroscopy may be necessary for further assessment. CT or MRI are not routinely recommended. Biomarkers have not been found to be clinically useful. Management of hyperplasia without atypia includes addressing reversible risk factors and considering progestogen treatment if regression does not occur. Weight loss and hormone therapy should be reviewed. Anovulatory cycles may regress with ovulation. Progestogen treatment may reduce the risk of progression to cancer. More evidence is needed to determine the appropriate management approach.\\n\\nMany women with endometrial hyperplasia may require treatment due to the risk of progression to cancer. The first-line medical treatment for hyperplasia without atypia is the levonorgestrel-releasing intrauterine system (LNG-IUS) due to its higher regression rate and fewer adverse effects compared to oral progestogens. Treatment should last for a minimum of 6 months to induce regression. Endometrial surveillance should be done every 6 months, with at least two consecutive negative biopsies before discharge. Surgical management, such as hysterectomy, should be considered if there is no regression after 12 months of treatment or if there is relapse. A laparoscopic approach to hysterectomy is preferred. Endometrial ablation is not recommended. Annual endometrial biopsies can be considered for high-risk women. Ultimately, treatment decisions should be based on individual factors and patient preferences.\\n\\nEndometrial ablation is not recommended for atypical hyperplasia, as complete endometrial destruction cannot be guaranteed, and there is a risk of tissue regeneration. Total hysterectomy is advised for women with atypical hyperplasia to reduce the risk of underlying malignancy or cancer progression. In cases where fertility preservation is desired or surgery is not suitable, first-line treatment with LNG-IUS is recommended, with oral progestogens as an alternative. Women should be counselled about the risks of fertility-sparing therapy, including the potential for cancer progression. Follow-up for women not undergoing hysterectomy should include routine endometrial surveillance with biopsies every 3 months until negative results are obtained. Women with atypical hyperplasia who wish to conceive should achieve disease regression before attempting to conceive and may consider assisted reproduction for higher live birth rates and to prevent relapse. It is important to monitor disease regression and consider referral to a fertility specialist for further assessment and treatment options.\\n\\n- A small trial showed that LNG-IUS treatment was more effective than observation alone in regressing simple hyperplasia and improving pregnancy rates in women with PCOS.\\n- Hysterectomy is recommended for women with atypical endometrial hyperplasia once fertility is no longer required.\\n- Systemic estrogen-only HRT should not be used in women with a uterus.\\n- Women with endometrial hyperplasia on HRT should consider switching to continuous progestogen intake using LNG-IUS or continuous combined HRT.\\n- Tamoxifen users should be aware of the increased risk of endometrial hyperplasia and cancer.\\n- Aromatase inhibitors do not increase the risk of endometrial pathology or vaginal bleeding.\\n- LNG-IUS may reduce the incidence of endometrial polyps and hyperplasia in women on tamoxifen.\\n- Women with endometrial hyperplasia while on tamoxifen should reassess the need for tamoxifen with their oncologist.\\n- Complete removal of endometrial polyps is recommended for management.\\n- Recommendations for future research include evaluating the role of biomarkers in diagnosing endometrial hyperplasia and studying the effect of weight loss on regression of the condition.\\n- Auditable topics include advising weight loss for obese women with endometrial hyperplasia and ensuring appropriate follow-up biopsies.\\n- Useful links and support groups for endometrial hyperplasia.\\n\\nAccuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia. Investigation of post-menopausal bleeding. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. Asymptomatic endometrial thickening. Endometrial thickness screening in premenopausal women with abnormal uterine bleeding. Long-term Consequences of Polycystic Ovary Syndrome. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Diagnostic dilation and curettage: a reappraisal. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20–74 years. Hysteroscopy with directed biopsy versus dilatation and curettage for the diagnosis of endometrial hyperplasia and cancer in perimenopausal women. A randomised trial comparing the H Pipelle with the standard Pipelle for endometrial sampling at ‘no-touch’ hysteroscopy. Ambulatory hysteroscopy. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia. The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women. Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. The behavior of endometrial hyperplasia: a prospective study. Bariatric surgery and endometrial pathology in asymptomatic morbidly obese women. Women at extreme risk for obesity-related carcinogenesis: Baseline endometrial pathology and impact of bariatric surgery on weight, metabolic profiles and quality of life. Endometrial histology in severely obese bariatric surgery candidates: an exploratory analysis. Referring survivors of endometrial cancer and complex atypical hyperplasia to bariatric specialists. Phytoestrogen consumption and endometrial cancer risk: a population-based case–control study. Histopathological findings of the endometrium in patients with dysfunctional uterine bleeding. Ovarian cysts in postmenopausal women. Management of suspected ovarian masses in premenopausal women. Inhibin as a marker for granulosa cell tumor. Granulosa cell tumor of the ovary. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia. Safer prescribing of therapeutic norethisterone for women at risk of venous thromboembolism. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in the treatment of simple endometrial hyperplasia without atypia. LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia. Levonorgestrel-releasing intrauterine system is an efficient therapeutic modality for simple endometrial hyperplasia. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Levonorgestrel-releasing intrauterine system as an effective treatment option for endometrial hyperplasia. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. The distal fallopian tube as the origin of non-uterine pelvic high-grade serous carcinomas. Supracervical hyster\\n\\nLong-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 2013;121:709–16. Intrauterine surgery using a new coaxial bipolar electrode in normal saline solution (Versapoint): a pilot study. Fertil Steril 1999;72:740–3. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol 2012; 207:266.e1–12. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet Gynecol 2010;116:365–73. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol 2012;124:542–8. American College of Obstetricians and Gynecologists, Society of Gynecologic Oncology. Practice Bulletin No. 149: Endometrial cancer. Obstet Gynecol 2015;125:1006–26. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol 2013;129:7–11. Fertility problems: assessment and treatment. NICE clinical guideline 156. Manchester: NICE; 2013. Efficacy of the levonorgestrel-releasing intrauterine system on IVF-ET outcomes in PCOS with simple endometrial hyperplasia. Reprod Sci 2015;22:758–66. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA1996;275:370–5.\\n\\nCommittee members from various locations contributed to the development of the guideline. The final version is the responsibility of the Guidelines Committee of the RCOG.\\n\\nPlease extract actionable suggestions from this analysis and format them as specified. For each suggestion, include detailed context with relevant quoted text from the guideline to help the user understand the reasoning behind the recommendation.\",\n  \"system_prompt\": \"You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \\n\\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\\n\\nCRITICAL CLINICAL REASONING REQUIREMENTS:\\n- You must first understand the specific clinical scenario and current diagnosis from the transcript\\n- Carefully assess whether each potential recommendation is APPROPRIATE and INDICATED for this specific case\\n- Apply the fundamental principle: \\\"Will this investigation or intervention change management or improve patient care in this specific scenario?\\\"\\n- Consider the clinical context: is this an acute emergency, established diagnosis, or uncertain diagnostic situation?\\n- Distinguish between situations where additional testing is needed vs. where diagnosis is already established\\n- Only recommend interventions that would genuinely improve patient care in THIS specific scenario\\n\\nGENERAL CLINICAL APPROPRIATENESS PRINCIPLES:\\n- Do NOT suggest diagnostic investigations when the diagnosis is already established through adequate clinical and/or imaging findings\\n- Do NOT recommend interventions that conflict with the current evidence-based management plan\\n- Do NOT suggest serial monitoring of biomarkers when the clinical picture and imaging provide sufficient diagnostic certainty\\n- Consider whether additional investigations would actually change the management approach\\n- Evaluate the timing: is this the appropriate point in the clinical course for this intervention?\\n- Apply cost-benefit analysis: does the potential benefit justify the intervention in this specific case?\\n\\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\\n{\\n  \\\"suggestions\\\": [\\n    {\\n      \\\"id\\\": \\\"1\\\",\\n      \\\"originalText\\\": \\\"text from transcript that needs changing OR description of missing element\\\",\\n      \\\"suggestedText\\\": \\\"proposed replacement text\\\",\\n      \\\"context\\\": \\\"detailed explanation of why this change is suggested, including relevant quoted text from the guideline in quotation marks, and confirmation that this recommendation is appropriate for the specific clinical scenario\\\",\\n      \\\"category\\\": \\\"addition|modification|deletion|formatting\\\",\\n      \\\"priority\\\": \\\"high|medium|low\\\",\\n      \\\"guidelineReference\\\": \\\"specific guideline section or rule\\\"\\n    }\\n  ]\\n}\\n\\nCRITICAL FORMATTING REQUIREMENTS:\\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\\n- Do not wrap the JSON in ```json or ``` blocks\\n- Start your response directly with { and end with }\\n- Use sequential numeric IDs starting from \\\"1\\\"\\n- Ensure all JSON is properly formatted and valid\\n\\nImportant guidelines for originalText field:\\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\\n- For ADDITIONS (missing elements): Use descriptive text like \\\"Missing: cervical length screening documentation\\\" or \\\"Gap: no discussion of antenatal corticosteroids\\\"\\n- DO NOT use phrases like \\\"no additional cervical length screening ordered\\\" unless those exact words appear in the transcript\\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\\n\\nImportant guidelines for context field:\\n- Provide detailed explanations including WHY the change is needed AND why it's appropriate for this specific case\\n- Include specific quoted text from the guideline using quotation marks (e.g., \\\"According to the guideline: 'All women should receive screening for...'\\\")\\n- Reference specific guideline recommendations or requirements\\n- Explain the clinical rationale behind the suggestion\\n- EXPLICITLY state why this recommendation is indicated in this particular clinical scenario\\n- Make the context informative and educational\\n\\nOther important guidelines:\\n- Only suggest changes that are explicitly supported by the guideline analysis AND clinically appropriate for the specific scenario\\n- Make suggestions specific and actionable\\n- For modifications, ensure original text selections are precise and findable in the transcript\\n- Prioritize suggestions based on clinical importance and appropriateness\\n- If no clinically appropriate suggestions can be made, return {\\\"suggestions\\\": []}\\n- When in doubt about appropriateness, err on the side of NOT making the suggestion\",\n  \"transcript_length\": 3778,\n  \"analysis_length\": 249,\n  \"guideline_id\": \"gtg-2014-endometrial-hyperplasia-pdf\",\n  \"guideline_title\": \"Management of Endometrial Hyperplasia\"\n}\n\nA: {\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Consider Mirena® IUD reinsertion if biopsy normal\",\n      \"suggestedText\": \"Recommend LNG-IUS (Mirena®) as first-line treatment if biopsy shows hyperplasia without atypia\",\n      \"context\": \"According to the guideline: 'The first-line medical treatment for hyperplasia without atypia is the levonorgestrel-releasing intrauterine system (LNG-IUS) due to its higher regression rate and fewer adverse effects compared to oral progestogens.' This patient has risk factors for endometrial hyperplasia (obesity, persistent AUB) and the current management plan should be updated to reflect guideline recommendations for first-line therapy if hyperplasia is confirmed.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"First-line treatment for hyperplasia without atypia\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"GYN OPD follow-up in 6/52 (consider hysteroscopy if bleeding persists)\",\n      \"suggestedText\": \"Schedule follow-up with endometrial surveillance every 6 months if hyperplasia confirmed, with at least two consecutive negative biopsies before discharge\",\n      \"context\": \"The guideline states: 'Endometrial surveillance should be done every 6 months, with at least two consecutive negative biopsies before discharge.' Given this patient's risk factors and current presentation, this more structured follow-up plan is indicated if hyperplasia is confirmed to monitor for regression and prevent progression.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Endometrial surveillance recommendations\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Missing: explicit documentation of WHO classification system application for any biopsy results\",\n      \"suggestedText\": \"Document biopsy results using WHO classification system (hyperplasia with/without atypia) when available\",\n      \"context\": \"The guideline specifies: 'The 2014 WHO classification separates endometrial hyperplasia into two groups based on cytological atypia.' This classification is critical for determining appropriate management and should be explicitly documented in the patient record when biopsy results are available.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"WHO classification system\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Start norethisterone 5mg TDS for 21/7 (to regulate bleeding)\",\n      \"suggestedText\": \"If biopsy shows hyperplasia without atypia, consider switching from oral norethisterone to LNG-IUS as primary treatment\",\n      \"context\": \"The guideline recommends: 'The first-line medical treatment for hyperplasia without atypia is the levonorgestrel-releasing intrauterine system (LNG-IUS) due to its higher regression rate and fewer adverse effects compared to oral progestogens.' While norethisterone is appropriate for acute bleeding control, long-term management should follow guideline recommendations if hyperplasia is confirmed.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Comparison of treatment efficacy\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Gap: no documented discussion of weight loss as management strategy\",\n      \"suggestedText\": \"Add recommendation for weight loss counseling given obesity as a risk factor for endometrial hyperplasia\",\n      \"context\": \"The guideline emphasizes: 'Weight loss and hormone therapy should be reviewed' for managing endometrial hyperplasia. This patient's BMI of 32 significantly increases her risk and weight loss should be incorporated as part of the management plan to address this modifiable risk factor.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Reversible risk factors\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"If biopsy shows hyperplasia → consider progestogens/hysterectomy (if completed family)\",\n      \"suggestedText\": \"If biopsy shows atypical hyperplasia → recommend total hysterectomy (given patient has completed family)\",\n      \"context\": \"The guideline states: 'Total hysterectomy is advised for women with atypical hyperplasia to reduce the risk of underlying malignancy or cancer progression.' As this patient is G4P2 and has completed her family, this would be the recommended management for atypical hyperplasia per guidelines.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Management of atypical hyperplasia\"\n    }\n  ]\n}\n\n--- Token Usage Report ---\nPrompt tokens: 4149\nCompletion tokens: 944\nTotal tokens: 5093\nEstimated cost: $0.002547",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 4149,
    "completion_tokens": 944,
    "total_tokens": 5093,
    "estimated_cost_usd": 0.0025465
  }
}